Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA is now requiring all GLP-1 medications — including Ozempic, Wegovy, Mounjaro, and Zepbound — to carry label warnings about a rare eye condition called NAION that can cause sudden, potentially permanent vision loss. The move follows a 2024 study and a Rutgers-led analysis linking these blockbuster drugs to a small but meaningful increase in risk. Patients experiencing sudden vision changes are urged to seek immediate medical attention.
The FDA has ordered class-wide label updates for all glucagon-like peptide-1 (GLP-1) receptor agonists — including Ozempic, Wegovy, Mounjaro, Zepbound, and Trulicity — to warn of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, painless, and sometimes permanent vision loss in one eye.
The agency's decision was triggered by a 2024 study on semaglutide and reinforced by a large Rutgers University analysis published in Annals of Internal Medicine, which found approximately 3–4 additional NAION cases per 10,000 GLP-1 users over 18 months compared to those on other diabetes medications. Risk appeared highest among men and adults aged 50–65.
By the Numbers
Why it matters: With millions of people on GLP-1 drugs for diabetes, obesity, and cardiovascular disease, even a rare side effect carries significant real-world impact. Clinicians should counsel patients — especially older men — to report sudden vision changes promptly and consider ophthalmology referral without delay.
